SGLT2抑制剂与糖尿病卒中患者血管内取栓后功能结局
这项多中心回顾性队列研究分析429例糖尿病急性缺血性卒中血管内取栓患者,其中51例(11.9%)取栓后使用SGLT2抑制剂。经倾向评分加权后,SGLT2抑制剂使用与3个月改良Rankin量表分布改善(共同OR 2.31,95%CI 1.30-4.10)及良好功能结局(OR 2.26,95%CI 1.15-4.43)相关,支持未来前瞻性试验。
要点
- 取栓后使用SGLT2抑制剂与3个月功能结局改善独立相关。
- 良好结局定义为3个月mRS 0-2,SGLT2i组OR 2.26(95%CI 1.15-4.43)。
- 各关键临床亚组间未见显著效应修饰,提示关联一致。
核心结论
- 糖尿病急性缺血性卒中患者血管内取栓后使用SGLT2抑制剂与3个月功能结局改善相关。
研究设计与样本
- 多中心回顾性队列研究,分析2020年1月至2025年3月韩国、意大利、瑞士4个综合卒中中心连续成人糖尿病取栓患者数据,共纳入429例。
- 采用重叠权重、逆概率治疗加权及1:1倾向评分匹配方法比较取栓后使用与未使用SGLT2抑制剂组。
主要发现
- 429例患者平均年龄73.5(SD 11.1)岁,男性249例(58.0%),初始NIHSS中位数12(IQR 6-18),51例(11.9%)取栓后使用SGLT2抑制剂。
- 成功再通率85.3%。
- 重叠权重模型(每组加权n=37)显示SGLT2抑制剂使用与3个月mRS分布改善相关(共同OR 2.31,95%CI 1.30-4.10)。
- 重叠权重模型中SGLT2抑制剂使用与良好结局(mRS 0-2) odds更高相关(OR 2.26,95%CI 1.15-4.43)。
- 逆概率治疗加权和倾向评分匹配模型结果一致,且逆概率治疗加权分析还显示与优异结局(mRS 0-1)显著相关。
临床怎么用
- 对于糖尿病急性缺血性卒中行血管内取栓的患者,取栓后使用SGLT2抑制剂可能改善3个月功能结局,但需前瞻性试验验证。
局限性
- 本研究为回顾性队列分析,样本量有限(SGLT2抑制剂组51例),可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although preclinical studies and limited clinical evidence suggest potential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) after acute ischemic stroke, their effects in patients with moderate-to-severe acute ischemic stroke requiring endovascular thrombectomy remain unclear. This study aimed to evaluate whether SGLT2i use after endovascular thrombectomy is associated with improved 3-month functional outcomes in diabetic patients with acute ischemic stroke. METHODS: This retrospective cohort study analyzed prospectively collected data from January 2020 to March 2025 across 4 comprehensive stroke centers in Korea, Italy, and Switzerland. Consecutive adult patients with diabetes were grouped according to whether SGLT2i was used after their endovascular thrombectomy. Propensity score-based methods-including overlap weighting, inverse probability of treatment weighting, and 1:1 propensity score matching-were applied. Outcomes included the shift in 3-month modified Rankin Scale score, favorable (modified Rankin Scale score 0-2), and excellent outcomes (modified Rankin Scale score 0-1) at 3 months. Ordinal and binary logistic regression analyses were performed. RESULTS: Of 429 eligible patients (mean [SD] age, 73.5 [11.1] years; 249 [58.0%] men; median [interquartile range] initial National Institutes of Health Stroke Scale score, 12 [6-18]), 51 (11.9%) received SGLT2i poststroke. Successful recanalization was achieved in 85.3%. In the overlap weighting model (weighted n=37 per group), SGLT2i use was associated with improved 3-month modified Rankin Scale score distribution (common odds ratio, 2.31; [95% CI, 1.30-4.10]) and higher odds of a favorable outcome (odds ratio, 2.26; [95% CI, 1.15-4.43]). Results were consistent across inverse probability of treatment weighting and propensity score matching models, with inverse probability of treatment weighting analyses additionally demonstrating significant associations with excellent outcomes. No significant effect modification was observed across key clinical subgroups. CONCLUSIONS: Poststroke SGLT2i therapy after endovascular thrombectomy was associated with improved 3-month functional outcomes in this multicenter retrospective analysis of diabetic patients. These findings suggest a potential therapeutic role for SGLT2i in poststroke diabetes management and support future prospective trials.
引用
- Yang W, Lee JS, Kim BJ, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Functional Outcomes After Endovascular Thrombectomy in Diabetic Stroke. Stroke. 2026. PMID: 42734063. doi:10.1161/STROKEAHA.126.056159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。